Reports FY23 revenue $1.784M, consensus $1.72M. “Our search for strategic alternatives did not yield an actionable proposal from a partner who could address our financial challenges and support the ongoing commercialization of Omisirge,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. “This restructuring transaction will enable Gamida Cell to remain a going concern and will support our ongoing efforts to make Omisirge available to more transplant centers and their patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMDA:
- Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
- Gamida Cell Revises Executive Compensation Amid Financial Constraints
- GMDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Gamida Cell data presented at 2024 Tandem Meetings of ASTCT, CIBMTR
- Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
